On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...
FibroBiologics, Inc., a biotechnology company focused on developing therapies for chronic diseases using fibroblasts, announced that Dr. Chuo Fang presented research at the Society for Investigative ...
Hosted on MSN
FBLG: Ready to transition to clinical-stage company
Phase 1/2 Diabetic Foot Ulcer Trial to Initiate in 1H26 FibroBiologics, Inc. (NASDAQ:FBLG) is preparing to initiate a Phase 1/2 clinical trial of CYWC628 in patients with refractory diabetic foot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results